Panakès Partners Launches €8.5 Million Fund for Lombardy MedTech

Panakès Partners has launched an €8.5 million investment vehicle aimed exclusively at MedTech and BioTech companies in Lombardy, according to EU-Startups. That is a modest cheque book by European venture standards — roughly the size of a single Series A round for a mid-stage health startup — but its regional focus makes it one of the more targeted instruments in the Italian market.

The figure matters for what it signals as much as what it funds. Eight-and-a-half million euros, deployed across early-stage companies, suggests the vehicle will write checks in the hundreds of thousands to low millions per deal rather than backing late-stage champions. Panakès has not yet disclosed the number of companies it intends to back, the ticket size, or the deployment timeline.

Lombardy is the deliberate choice here, not an accident of geography. The region around Milan hosts one of Italy's densest clusters of hospitals, research institutions, and life-science companies, and it regularly accounts for a disproportionate share of the country's private biomedical activity. A fund scoped to a single region can move faster and work closer with local hospitals and universities — though it also concentrates risk in one ecosystem.

What does the vehicle actually target?

The mandate covers two sectors: medical technology and biotechnology. EU-Startups reports no broader thematic scope, no later-stage expansion clause, and no geographic carve-out beyond Lombardy.

The open questions are the ones investors will ask first:

• How many portfolio companies does the €8.5 million cover?
• Is the capital first-money-in or follow-on?
• Are public or regional institutions co-investing alongside Panakès?

None of these details appear in the announcement as reported. In plain words: the strategy is clear, the mechanics are not.

Why a regional MedTech fund now?

Italy's deep-tech and life-science startups have struggled for decades with a structural problem — domestic capital thins out sharply once companies need rounds beyond a few million euros. Funds like Panakès were built in part to close that gap. An €8.5 million vehicle does not close it; it seeds it at the earliest stage.

The regional framing also aligns with how Italian innovation policy has trended: money follows clusters, and Lombardy's medical cluster is the country's strongest claim to one. Whether a regionally capped fund can produce companies that scale nationally is the test the vehicle will now face.

Panakès Partners, based in Milan, has made venture investing in healthcare and deep tech its core business. The firm has not publicly set a closing date for the vehicle or announced first investments.

The takeaway: a small, sharply aimed fund has entered Italy's richest medical region, and its first deals will reveal whether €8.5 million is a catalyst or a rounding error.